Comments
Natco Pharma has launched generic version of pomalidomide capsules for treatment of blood cancer in the domestic market.
Pomalidomide is sold by Celgene Inc in the US under the brand Pomalyst. The Hyderabad-based Natco markets its generic pomalidomide capsules under the brand name Polalid, the company said in a release.
Pomalidomide is a thalidomide analogue indicated, in combination with dexamethasone, for patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Natco has priced Pomalid 1 mg, 2 mg, and 4 mg capsules at ₹5,000, ₹10,000 and ₹20,000 respectively, for a monthly pack of 21 capsules.
“We believe, this is approximately 98 per cent discounted price from what it is sold in the US to patients, as per secondary market data,” the company added.
The company’s scrip remained flat on the BSE at ₹896 on Wednesday.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.